This Study evaluates the possible drug interaction between FosD and verapamil when taken together.

An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers when Fostamatinib Disodium 150 mg is Administered Alone and in Combination with Verapamil.

Inclusion Criteria:

• Weight of at least 50 kg (110 lbs) and body mass index (BMI) between 18 and 35 kg/m2, inclusive.
• Females must be of non-childbearing potential

Exclusion Criteria:

• History of clinically significant disease or disorder or presence of GI, hepatic or renal disease
• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the drug
• Any clinically significant abnormalities in lab safety tests or vital signs as results as judged by the Investigator
• Use of prescription or over-the-counter drugs within 2 weeks of first administration of investigational product
• Current smokers or use of nicotine products within 1 month prior to enrollment